Zoetis Inc. (NYSE:ZTS) Shares Sold by Ninety One North America Inc.

Ninety One North America Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 11.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,282 shares of the company’s stock after selling 430 shares during the quarter. Ninety One North America Inc.’s holdings in Zoetis were worth $535,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. E. Ohman J or Asset Management AB lifted its position in shares of Zoetis by 11.6% during the 4th quarter. E. Ohman J or Asset Management AB now owns 20,750 shares of the company’s stock worth $3,381,000 after buying an additional 2,150 shares during the last quarter. Mather Group LLC. raised its stake in Zoetis by 4.6% during the 4th quarter. Mather Group LLC. now owns 3,398 shares of the company’s stock worth $554,000 after acquiring an additional 148 shares in the last quarter. Rockline Wealth Management LLC lifted its position in Zoetis by 4.5% in the fourth quarter. Rockline Wealth Management LLC now owns 5,823 shares of the company’s stock valued at $949,000 after acquiring an additional 252 shares during the last quarter. Calamos Wealth Management LLC boosted its stake in Zoetis by 21.0% in the fourth quarter. Calamos Wealth Management LLC now owns 84,030 shares of the company’s stock valued at $13,691,000 after acquiring an additional 14,568 shares in the last quarter. Finally, Calamos Advisors LLC grew its holdings in shares of Zoetis by 15.0% during the fourth quarter. Calamos Advisors LLC now owns 210,885 shares of the company’s stock worth $34,359,000 after purchasing an additional 27,579 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.2 %

Shares of NYSE:ZTS opened at $172.24 on Wednesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The firm’s 50-day simple moving average is $169.48 and its 200-day simple moving average is $179.39. The company has a market cap of $77.71 billion, a price-to-earnings ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.36 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is a boost from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.16%. Zoetis’s dividend payout ratio is presently 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus decreased their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Morgan Stanley cut their target price on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.